What high-risk features for stage I NSCLC would lead you to consider adjuvant osimertinib?

In patients with resected stage IB non-small cell lung cancer (NSCLC) harboring EGFR mutations, adjuvant osimertinib may be considered for care. There is some evolving data that there may be some benefit in the presence of other risk factors in stage I, including solid or micropapillary histologic c...